ZA200801575B - Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily - Google Patents

Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily

Info

Publication number
ZA200801575B
ZA200801575B ZA200801575A ZA200801575A ZA200801575B ZA 200801575 B ZA200801575 B ZA 200801575B ZA 200801575 A ZA200801575 A ZA 200801575A ZA 200801575 A ZA200801575 A ZA 200801575A ZA 200801575 B ZA200801575 B ZA 200801575B
Authority
ZA
South Africa
Prior art keywords
guanfacine
composition
single dose
pharmaceutical formulations
dose form
Prior art date
Application number
ZA200801575A
Other languages
English (en)
Inventor
Amir H Shojaei
Pennick Michael
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37668083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200801575(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Llc filed Critical Shire Llc
Publication of ZA200801575B publication Critical patent/ZA200801575B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200801575A 2005-07-28 2008-02-18 Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily ZA200801575B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70298205P 2005-07-28 2005-07-28

Publications (1)

Publication Number Publication Date
ZA200801575B true ZA200801575B (en) 2008-12-31

Family

ID=37668083

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801575A ZA200801575B (en) 2005-07-28 2008-02-18 Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily

Country Status (18)

Country Link
US (1) US20070048371A1 (xx)
EP (1) EP1909766B1 (xx)
JP (2) JP5726401B2 (xx)
KR (1) KR20080041669A (xx)
CN (1) CN101252917A (xx)
AR (1) AR054595A1 (xx)
AU (1) AU2006275718B8 (xx)
BR (1) BRPI0615989B8 (xx)
CA (1) CA2616181C (xx)
DK (1) DK1909766T3 (xx)
ES (1) ES2566395T3 (xx)
IL (1) IL188980A0 (xx)
NO (1) NO20081038L (xx)
NZ (1) NZ565649A (xx)
RU (1) RU2435573C2 (xx)
TW (1) TW200744672A (xx)
WO (1) WO2007016284A2 (xx)
ZA (1) ZA200801575B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
ES2733133T3 (es) * 2010-02-03 2019-11-27 Pharma Two B Ltd Formulaciones de liberación prolongada de rasagilina y sus usos
AU2011265293A1 (en) * 2010-06-11 2013-01-24 Shire Llc Combination therapy with lisdexamphetamine and extended release guanfacine
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
CN105188677A (zh) 2013-03-13 2015-12-23 特瑞斯制药股份有限公司 苯佐那酯调释固体片剂和胶囊剂
US9180104B2 (en) * 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
WO2016089997A1 (en) 2014-12-02 2016-06-09 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
SG11201804100UA (en) * 2015-12-08 2018-06-28 Ardea Biosciences Inc Pharmaceutical composition comprising a potent inhibitor of urat1
JP6656670B2 (ja) * 2016-03-11 2020-03-04 国立大学法人 鹿児島大学 抗ｈｃｖ活性を有する薬剤
HUE059844T2 (hu) * 2016-04-20 2023-01-28 New Frontier Labs Llc Azelainsav-észterek az inzulin-rezisztencia kezelésében
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
EP4292587A1 (en) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Guanfacine hydrochloride containing pharmaceutical preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649918A5 (de) * 1981-07-09 1985-06-28 Sandoz Ag Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
DE19834573A1 (de) * 1998-07-31 2000-02-03 Bayer Ag Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
DK1355633T3 (da) * 2001-12-19 2005-04-04 Astrazeneca Ab Ny filmcoating, der indeholder en ethylacrylat/methylmethacrylat-copolymer og polyvinylacetat
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
ATE401860T1 (de) * 2002-03-29 2008-08-15 Alza Corp Volumensparende arzneiform zur kontrollierten freisetzung
US6763509B2 (en) * 2002-09-26 2004-07-13 Sun Microsystems, Inc. Method and apparatus for allocating decoupling capacitor cells
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties

Also Published As

Publication number Publication date
DK1909766T3 (en) 2016-04-04
EP1909766B1 (en) 2016-03-16
TW200744672A (en) 2007-12-16
JP2009502951A (ja) 2009-01-29
RU2435573C2 (ru) 2011-12-10
ES2566395T3 (es) 2016-04-12
AR054595A1 (es) 2007-06-27
AU2006275718B2 (en) 2012-10-04
BRPI0615989A2 (pt) 2011-05-31
BRPI0615989B1 (pt) 2020-05-26
WO2007016284A3 (en) 2007-03-29
WO2007016284A2 (en) 2007-02-08
CN101252917A (zh) 2008-08-27
NZ565649A (en) 2011-03-31
JP2012229253A (ja) 2012-11-22
AU2006275718B8 (en) 2012-11-01
US20070048371A1 (en) 2007-03-01
IL188980A0 (en) 2008-08-07
CA2616181C (en) 2015-02-17
CA2616181A1 (en) 2007-02-08
NO20081038L (no) 2008-04-23
EP1909766A2 (en) 2008-04-16
AU2006275718A8 (en) 2012-11-01
BRPI0615989B8 (pt) 2021-05-25
AU2006275718A1 (en) 2007-02-08
KR20080041669A (ko) 2008-05-13
RU2008102911A (ru) 2009-09-10
JP5726401B2 (ja) 2015-06-03

Similar Documents

Publication Publication Date Title
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
ZA200900345B (en) Preparation of pharmaceutical formulations
IL185390A (en) A solid dosage form
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL221770A (en) Edamantyl acetamide derivatives, the pharmaceutical composition containing them and its use in the preparation of a drug
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
EP1615621A4 (en) COMPOSITIONS FOR ADMINISTERING DRUG COMBINATIONS
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
IL176519A0 (en) Directly compressible pharmaceutical composition for the oral administration of cci-779
EP2078731A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
EP1631239A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE COMPOUNDS OF VITAMIN D
IL179456A0 (en) Dosage form for delivery of multiple drug forms
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
EP1862183A4 (en) PHARMACEUTICAL COMPOSITION WITH HEAVY WATER-SOLUBLE MEDICAMENT
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
EP1830831A4 (en) PHARMACEUTICAL FORMULATIONS CONTAINING GALLIUM SALTS
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
IL183930A0 (en) Use of cladribine for preparation of pharmaceutical compositions
EP2206519A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF